The earnings call reflects a positive sentiment driven by strong growth in LUMRYZ adoption and favorable legal outcomes, alongside raised financial guidance. However, some caution remains due to typical Q1 seasonality effects and potential impacts from ongoing legal and tariff challenges.

Company Guidance -

Q3 2025

During Avadel Pharmaceuticals' First Quarter 2025 earnings call, the company provided several important metrics and updates, highlighting their confidence in continued growth. LUMRYZ, their key product, experienced significant progress with accelerated patient adoption, leading to 100% growth in patient numbers compared to the same period last year, ending the quarter with 2,800 patients. Additionally, the net new patient count increased by 50% from the previous quarter, with 300 new patients starting therapy. Despite typical Q1 seasonality, Avadel reported $52.5 million in net revenue, marking over 90% growth versus Q1 2024. The company raised its full-year revenue guidance to a range of $255 million to $265 million, up from the previous guidance of $240 million to $260 million, and expects to end the year with 3,400 to 3,600 patients on LUMRYZ. Their strategic investments, including a 15% increase in sales force and doubled field reimbursement and nursing support teams, have been instrumental in improving patient enrollments, new patient starts, and persistency rates, driving continued momentum and growth throughout 2025.

Strong Growth in LUMRYZ Adoption

LUMRYZ saw accelerated patient adoption with 2,800 patients by the end of Q1 2025, reflecting 100% growth over the same period last year.

Favorable Court Decision

Avadel received a favorable decision from the Federal Circuit Court of Appeals, allowing them to pursue additional indications for LUMRYZ beyond narcolepsy.

Increased Financial Guidance

Avadel raised its full year 2025 revenue guidance to $255 million to $265 million, up from $240 million to $260 million.

Expansion of Commercial Teams

Avadel expanded its sales force by 15% and doubled the size of both its field reimbursement and nursing support teams, contributing to increased patient starts and improved persistency.

Substantial Revenue Growth

Reported net revenue of $52.5 million in Q1 2025, representing greater than 90% growth versus Q1 2024.

Avadel Pharmaceuticals (AVDL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AVDL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.08 / -	-0.03	―	―	―
Aug 07, 2025	2025 (Q2)	0.03 / 0.10	-0.14	171.43% (+0.24)
May 07, 2025	2025 (Q1)	-0.07 / -0.05	-0.3	83.33% (+0.25)
Mar 03, 2025	2024 (Q4)	-0.04 / -0.05	-0.32	84.38% (+0.27)
Nov 12, 2024	2024 (Q3)	-0.08 / -0.03	-0.41	92.68% (+0.38)	―
Aug 08, 2024	2024 (Q2)	-0.18 / -0.14	-0.83	83.13% (+0.69)
May 08, 2024	2024 (Q1)	-0.23 / -0.30	-0.48	37.50% (+0.18)	―
Mar 04, 2024	2023 (Q4)	-0.28 / -0.32	-0.44	27.27% (+0.12)	―
Nov 08, 2023	2023 (Q3)	-0.37 / -0.41	-0.33	-24.24% (-0.08)	―
Aug 09, 2023	2023 (Q2)	-0.36 / -0.83	-1.07	22.43% (+0.24)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AVDL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$8.64	$9.47	+9.61%
Mar 03, 2025	$7.91	$7.55	-4.55%
Nov 12, 2024	$16.30	$13.15	-19.33%
Aug 08, 2024	$16.10	$15.74	-2.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Avadel Pharmaceuticals (AVDL) report earnings?

Avadel Pharmaceuticals (AVDL) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Avadel Pharmaceuticals (AVDL) earnings time?

Avadel Pharmaceuticals (AVDL) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AVDL EPS forecast?

AVDL EPS forecast for the fiscal quarter 2025 (Q3) is 0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing